SCHEMBL1307173

SCHEMBL1307173

CN(C)CCCNC1CCN(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.57
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
CYP2C19 P33261 1/20 0.55
KDM4E B2RXH2 1/20 0.55
CHRM2 P08172 3/20 0.54
CHRM5 P08912 3/20 0.54
CHRM3 P20309 2/20 0.54
HTT P42858 1/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
ALDH1A1 P00352 2/20 0.52
GRIN2B Q13224 3/20 0.50
CHRM1 P11229 1/20 0.50
DRD2 P14416 1/20 0.50
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
ENPP2 Q13822 1/20 0.48
USP2 O75604 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1308273 0.97 SMN1; SMN2 (0.56) SMN1; SMN2NPC1RAB9ACYP2C19KDM4E
SCHEMBL5866379 0.90 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9ACYP2C19KDM4E
SCHEMBL28592826 0.88 SMN1; SMN2 (0.60) SMN1; SMN2NPC1RAB9ACYP2C19KDM4E
SCHEMBL22587630 0.87 SMN1; SMN2 (0.58) SMN1; SMN2NPC1RAB9ACYP2C19KDM4E
SCHEMBL5866443 0.87 SMN1; SMN2 (0.58) SMN1; SMN2NPC1RAB9ACYP2C19KDM4E
SCHEMBL1972315 0.87 SMN1; SMN2 (0.64) SMN1; SMN2NPC1RAB9ACYP2C19KDM4E
SCHEMBL5866409 0.86 SMN1; SMN2 (0.60) SMN1; SMN2NPC1RAB9ACYP2C19KDM4E
SCHEMBL26510682 0.86 SMN1; SMN2 (0.62) SMN1; SMN2NPC1RAB9ACYP2C19KDM4E
Hydrochloric Acid SCHEMBL16992484 0.85 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9ACYP2C19KDM4E
SCHEMBL5866369 0.85 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9ACYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8053457-B2 3-imidazolyl-indoles for the treatment of proliferative diseases NOVARTIS AG (CH) 2011-11-08 US disclosed
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases NOVARTIS AG (CH) 2010-05-20 US disclosed
EP-2142535-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis Ag (CH) 2010-01-13 EP disclosed
WO-2008119741-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases MDM4, TP53, MDM2 SMN1; SMN2 2884/4885NPC1 4455/4885RAB9A 2062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.